Among participants allocated to rosuvastatin , 221 fractures were confirmed , compared with 210 among those allocated to placebo , such that the incidence of fracture in the rosuvastatin and placebo groups was 1.20 and 1.14 per 100 person-years , respectively ( adjusted HR , 1.06 [ 95 % CI , 0.88-1 .28 ] ; P = .53 ) .